Ardelyx Stock Performance
| ARDX Stock | USD 5.12 0.20 4.07% |
The firm shows a Beta (market volatility) of 2.34, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ardelyx will likely underperform. At this point, Ardelyx has a negative expected return of -0.23%. Please make sure to confirm Ardelyx's total risk alpha, as well as the relationship between the skewness and day median price , to decide if Ardelyx performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ardelyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.14 | Five Day Return 3.61 | Year To Date Return (16.94) | Ten Year Return (77.97) | All Time Return (64.39) |
1 | Investors in Ardelyx, Inc. Should Contact Levi Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX | 10/09/2024 |
2 | Shareholders that lost money on Ardelyx, Inc. should contact Levi Korsinsky about pending Class Action - ARDX | 10/14/2024 |
3 | Ardelyx, Inc.s Shares Lagging The Industry But So Is The Business | 10/24/2024 |
4 | Michael Raab Sells 25,000 Shares of Ardelyx, Inc. Stock | 10/31/2024 |
5 | Earnings call Ardelyx reports solid growth amid Medicare challenges | 11/01/2024 |
6 | Disposition of 27172 shares by David Rosenbaum of Ardelyx at 2.32 subject to Rule 16b-3 | 11/04/2024 |
7 | Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference | 11/05/2024 |
8 | Ardelyx chief development officer sells shares worth 165,743 | 11/08/2024 |
9 | Ardelyx shares downgraded amid sales concerns for XPHOZAH | 11/11/2024 |
10 | Acquisition by Mott David M of 215868 shares of Ardelyx at 4.6167 subject to Rule 16b-3 | 11/13/2024 |
11 | Insider Selling Ardelyx, Inc. CEO Sells 2,743 Shares of Stock | 11/15/2024 |
12 | Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference | 11/20/2024 |
| Begin Period Cash Flow | 96.1 M |
Ardelyx |
Ardelyx Relative Risk vs. Return Landscape
If you would invest 631.00 in Ardelyx on August 24, 2024 and sell it today you would lose (119.00) from holding Ardelyx or give up 18.86% of portfolio value over 90 days. Ardelyx is currently does not generate positive expected returns and assumes 4.4447% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Ardelyx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ardelyx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ardelyx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ardelyx, and traders can use it to determine the average amount a Ardelyx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0516
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ARDX |
Estimated Market Risk
| 4.44 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ardelyx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ardelyx by adding Ardelyx to a well-diversified portfolio.
Ardelyx Fundamentals Growth
Ardelyx Stock prices reflect investors' perceptions of the future prospects and financial health of Ardelyx, and Ardelyx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ardelyx Stock performance.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 1.08 B | ||||
| Shares Outstanding | 236.85 M | ||||
| Price To Earning | (2.11) X | ||||
| Price To Book | 7.36 X | ||||
| Price To Sales | 4.63 X | ||||
| Revenue | 124.46 M | ||||
| Gross Profit | 15.54 M | ||||
| EBITDA | (55.35 M) | ||||
| Net Income | (66.07 M) | ||||
| Cash And Equivalents | 90.62 M | ||||
| Cash Per Share | 0.48 X | ||||
| Total Debt | 55.98 M | ||||
| Debt To Equity | 0.56 % | ||||
| Current Ratio | 2.31 X | ||||
| Book Value Per Share | 0.67 X | ||||
| Cash Flow From Operations | (89.72 M) | ||||
| Earnings Per Share | (0.32) X | ||||
| Market Capitalization | 1.17 B | ||||
| Total Asset | 297.58 M | ||||
| Retained Earnings | (846.2 M) | ||||
| Working Capital | 195.72 M | ||||
| Current Asset | 112.03 M | ||||
| Current Liabilities | 7.72 M | ||||
About Ardelyx Performance
Evaluating Ardelyx's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Ardelyx has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ardelyx has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 255.33 | 268.09 | |
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | (0.40) | (0.38) |
Things to note about Ardelyx performance evaluation
Checking the ongoing alerts about Ardelyx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ardelyx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ardelyx generated a negative expected return over the last 90 days | |
| Ardelyx has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 124.46 M. Net Loss for the year was (66.07 M) with profit before overhead, payroll, taxes, and interest of 15.54 M. | |
| Ardelyx currently holds about 90.62 M in cash with (89.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48. | |
| Ardelyx has a very weak financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference |
- Analyzing Ardelyx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ardelyx's stock is overvalued or undervalued compared to its peers.
- Examining Ardelyx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ardelyx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ardelyx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ardelyx's stock. These opinions can provide insight into Ardelyx's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Ardelyx Stock Analysis
When running Ardelyx's price analysis, check to measure Ardelyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ardelyx is operating at the current time. Most of Ardelyx's value examination focuses on studying past and present price action to predict the probability of Ardelyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ardelyx's price. Additionally, you may evaluate how the addition of Ardelyx to your portfolios can decrease your overall portfolio volatility.